All In Biotech

Free tool

FAERS Monitor: Rezzayo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217417 or its brand name (Rezzayo, Rezafungin Acetate). Reports on generic versions are filed under their own applications.

Reports

101

Serious

46

46% of reports

Hospitalization

19

Death reported

18

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use41
  • product prescribing issue12
  • no adverse event11
  • drug ineffective9
  • death6
  • renal impairment5
  • condition aggravated4
  • fungal infection4
  • product dose omission issue4
  • product use issue4
  • blood bilirubin increased3
  • candida infection3
  • cerebral haemorrhage3
  • cholecystitis acute3
  • dizziness3

Reports by year received

View as table
YearReports
20222
20232
202458
202510
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product prescribing issueSignal12114.867.51,243
cholecystitis acuteSignal3110.336.2225
candida infectionSignal337.012.172
fungal infectionSignal425.09.670
blood bilirubin increasedSignal323.17.643
cerebral haemorrhageSignal317.55.732
no adverse eventSignal1112.67.2108
renal impairmentSignal512.45.342
off label useSignal419.87.7327
product use issueSignal44.41.78
product dose omission issue42.81.13
condition aggravated42.71.03
death61.50.70
drug ineffective91.40.81
dizziness31.30.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.